ARID1A was described as often mutated in various types of tumors, such as clear cell ovarian cancer (45%), endometrial cancer (37%), GC (20–30%), bladder cancer (20%), hepatocellular cancer (14%), melanomas (12%), colorectal cancer (9%), lung cancer (8%), pancreatic cancer (4%), and breast cancer (3%) [30]. Here, ARID1A is linked to breast carcinoma.